1
|
Thomson CG, Aicher TD, Cheng W, Du H, Dudgeon C, Li AH, Li B, Lightcap E, Luo D, Mulvihill M, Pan P, Rahemtulla BF, Rigby AC, Sherborne B, Sood S, Surguladze D, Talbot EPA, Tameire F, Taylor S, Wang Y, Wojnarowicz P, Xiao F, Ramurthy S. Discovery of HC-7366: An Orally Bioavailable and Efficacious GCN2 Kinase Activator. J Med Chem 2024; 67:5259-5271. [PMID: 38530741 DOI: 10.1021/acs.jmedchem.3c02384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/28/2024]
Abstract
A series of activators of GCN2 (general control nonderepressible 2) kinase have been developed, leading to HC-7366, which has entered the clinic as an antitumor therapy. Optimization resulted in improved permeability compared to that of the original indazole hinge binding scaffold, while maintaining potency at GCN2 and selectivity over PERK (protein kinase RNA-like endoplasmic reticulum kinase). The improved ADME properties of this series led to robust in vivo compound exposure in both rats and mice, allowing HC-7366 to be dosed in xenograft models, demonstrating that activation of the GCN2 pathway by this compound leads to tumor growth inhibition.
Collapse
Affiliation(s)
- Christopher G Thomson
- Integrated Drug Discovery Services, Pharmaron UK Ltd., West Hill Innovation Park, Hertford Road, Hoddesdon, Hertfordshire EN11 9FH, U.K
| | - Thomas D Aicher
- Department of Chemistry, Lycera Corporation, Ann Arbor, Michigan 48103, United States
| | - Weiwei Cheng
- Pharmaron Beijing, Company Ltd., No. 6, TaiHe Road, BDA, Beijing 100176, China
| | - Hongwen Du
- Pharmaron Beijing, Company Ltd., No. 6, TaiHe Road, BDA, Beijing 100176, China
| | - Crissy Dudgeon
- HiberCell Inc., 619 West 54th Street, New York, New York 10019, United States
| | - An-Hu Li
- HiberCell Inc., 619 West 54th Street, New York, New York 10019, United States
| | - Baozhong Li
- Pharmaron Beijing, Company Ltd., No. 6, TaiHe Road, BDA, Beijing 100176, China
| | - Eric Lightcap
- HiberCell Inc., 619 West 54th Street, New York, New York 10019, United States
| | - Diheng Luo
- Pharmaron Xi'an, Company Ltd., No. 1, 12th Fengcheng Road, Xi'an 710018, China
| | - Mark Mulvihill
- HiberCell Inc., 619 West 54th Street, New York, New York 10019, United States
| | - Pengwei Pan
- Pharmaron Beijing, Company Ltd., No. 6, TaiHe Road, BDA, Beijing 100176, China
| | - Benjamin F Rahemtulla
- Integrated Drug Discovery Services, Pharmaron UK Ltd., West Hill Innovation Park, Hertford Road, Hoddesdon, Hertfordshire EN11 9FH, U.K
| | - Alan C Rigby
- HiberCell Inc., 619 West 54th Street, New York, New York 10019, United States
| | - Bradley Sherborne
- Integrated Drug Discovery Services, Pharmaron UK Ltd., West Hill Innovation Park, Hertford Road, Hoddesdon, Hertfordshire EN11 9FH, U.K
| | - Sanjeev Sood
- Preformulation and Preclinical Services, Pharmaron UK Ltd., West Hill Innovation Park, Hertford Road, Hoddesdon, Hertfordshire EN11 9FH, U.K
| | - David Surguladze
- HiberCell Inc., 619 West 54th Street, New York, New York 10019, United States
| | - Eric P A Talbot
- Integrated Drug Discovery Services, Pharmaron UK Ltd., West Hill Innovation Park, Hertford Road, Hoddesdon, Hertfordshire EN11 9FH, U.K
| | - Feven Tameire
- HiberCell Inc., 619 West 54th Street, New York, New York 10019, United States
| | - Simon Taylor
- Integrated Drug Discovery Services, Pharmaron UK Ltd., West Hill Innovation Park, Hertford Road, Hoddesdon, Hertfordshire EN11 9FH, U.K
| | - Yi Wang
- Pharmaron Beijing, Company Ltd., No. 6, TaiHe Road, BDA, Beijing 100176, China
| | - Paulina Wojnarowicz
- HiberCell Inc., 619 West 54th Street, New York, New York 10019, United States
| | - Fenfen Xiao
- Pharmaron Xi'an, Company Ltd., No. 1, 12th Fengcheng Road, Xi'an 710018, China
| | - Savithri Ramurthy
- HiberCell Inc., 619 West 54th Street, New York, New York 10019, United States
| |
Collapse
|
2
|
Afratis K, Bateman JM, Rahemtulla BF, Hughes O, Milgram BC, Mulhern TA, Talbot EPA. Regioselective Synthesis of Fully Substituted Fused Pyrroles through an Oxidant-Free Multicomponent Reaction. Org Lett 2023; 25:461-465. [PMID: 36638117 DOI: 10.1021/acs.orglett.2c03889] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
The synthesis of fully substituted fused pyrroles through a multicomponent reaction between a thioamide, an aldehyde, and ammonium acetate is described. This process improves on a route commonly employed in the patent literature by avoiding the use of potentially hazardous oxidants, which cause the formation of side products and require a stringent process of derisking to be utilized on scale. The reaction proceeds under mild conditions, displays excellent functional group tolerance, and facilitates diversification through multiple vectors.
Collapse
Affiliation(s)
- Konstantinos Afratis
- Pharmaron Drug Discovery Services Europe, Pharmaron UK Ltd., Hertford Road, HoddesdonEN11 9FH, United Kingdom
| | - Joseph M Bateman
- Pharmaron Drug Discovery Services Europe, Pharmaron UK Ltd., Hertford Road, HoddesdonEN11 9FH, United Kingdom
| | - Benjamin F Rahemtulla
- Pharmaron Drug Discovery Services Europe, Pharmaron UK Ltd., Hertford Road, HoddesdonEN11 9FH, United Kingdom
| | - Oliver Hughes
- Pharmaron Drug Discovery Services Europe, Pharmaron UK Ltd., Hertford Road, HoddesdonEN11 9FH, United Kingdom
| | - Benjamin C Milgram
- Scorpion Therapeutics Inc., One Winthrop Square, Suite 400, Boston, Massachusetts02110, United States
| | - Thomas A Mulhern
- Vector CMC Consulting LLC, 5155 Trumpeter Dr., Portage, Michigan49024, United States
| | - Eric P A Talbot
- Pharmaron Drug Discovery Services Europe, Pharmaron UK Ltd., Hertford Road, HoddesdonEN11 9FH, United Kingdom
| |
Collapse
|
4
|
Rahemtulla BF, Clark HF, Smith MD. Catalytic Enantioselective Synthesis of C 1 - and C 2 -Symmetric Spirobiindanones through Counterion-Directed Enolate C-Acylation. Angew Chem Int Ed Engl 2016; 55:13180-13183. [PMID: 27628946 PMCID: PMC5113699 DOI: 10.1002/anie.201607731] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2016] [Indexed: 01/19/2023]
Abstract
A catalytic enantioselective route to C1 - and C2 -symmetric 2,2'-spirobiindanones has been realized through an intramolecular enolate C-acylation. This reaction employs a chiral ammonium counterion to direct the acylation of an in situ generated ketone enolate with a pentafluorophenyl ester. This reaction constitutes the first example of a direct catalytic enantioselective C-acylation of a ketone and provides an efficient and highly enantioselective route to axially chiral spirobiindanediones. These products can be diastereoselectively derivatized, offering access to a range of functionalized spirocyclic architectures.
Collapse
Affiliation(s)
- Benjamin F Rahemtulla
- Chemistry Research Laboratory, University of Oxford, 12 Mansfield Road, Oxford, OX1 3TA, UK
| | - Hugh F Clark
- GlaxoSmithKline Pharmaceuticals, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK
| | - Martin D Smith
- Chemistry Research Laboratory, University of Oxford, 12 Mansfield Road, Oxford, OX1 3TA, UK.
| |
Collapse
|